Synonyms: AG-1343 | AG1343 | Viracept®
nelfinavir is an approved drug (FDA (1997))
Compound class:
Synthetic organic
Comment: Nelfinavir is an oral antiretroviral drug. It inhibits human immunodeficiency virus (HIV) protease.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Nelfinavir is used to treat HIV infection, usually in combination with other antiretroviral drugs. EMA marketing authorisation (granted in 1998) was later withdrawn. Nelfinavir has anti-cancer activity and radiosensitizing effects and has advanced to clinical trials for solid tumours and hematological malignancies. It is also being repositioned for COVID-19, having demonstrated antiviral activity against SARS-CoV-2 [1]. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03256916 | Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix | Phase 3 Interventional | Tata Memorial Hospital | ||
NCT02188537 | Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma | Phase 2 Interventional | Swiss Group for Clinical Cancer Research |
External links |
For extended ADME data see the following: Drugs.com |